Killed Bacillus subtilis spores expressing streptavidin: A novel carrier of drugs to target cancer cells

Journal of Drug Targeting

Volumn 21, Issue 6, 2013, Pages 528-541

  Nguyen, Van Anh Thi ^a   Huynh, Hong Anh ^b   Hoang, Tong Van ^c   Ninh, Ngoc Thi ^a   Pham, An Thi Hong ^a   Nguyen, Hoa Anh ^a,d   Phan, Tuan Nghia ^a   Cutting, Simon M ^b  

^a VIETNAM NATIONAL UNIVERSITY   (Viet Nam)

^b UNIVERSITY OF LONDON   (United Kingdom)

^c VIETNAM MILITARY MEDICAL UNIVERSITY   (Viet Nam)

^d ANABIO Research and Development JSC   (Viet Nam)

Author keywords

Bacillus subtilis spores; Biotinylated cetuximab; Colon cancer cells; Drug delivery; SA1 cetuximab; Streptavidin

Indexed keywords

BACTERIAL PROTEIN; CELL DNA; CETUXIMAB; COTB PROTEIN; DRUG CARRIER; PACLITAXEL; STREPTAVIDIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BACILLUS SUBTILIS; BACTERIAL SPORE; BIOTINYLATION; CANCER CELL CULTURE; CANCER INHIBITION; CELL DIVISION; CELL STRAIN HT29; CHIMERA; COMPLEX FORMATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA CONTENT; DRUG POTENTIATION; FLUORESCENCE; HUMAN; HUMAN CELL; IC 50; POLYPLOIDY; PRIORITY JOURNAL; TARGET CELL DESTRUCTION;

ADSORPTION; ANTIBODIES, MONOCLONAL, HUMANIZED; BACILLUS SUBTILIS; BACTERIAL PROTEINS; CELL DIVISION; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; HT29 CELLS; HUMANS; HYDROGEN-ION CONCENTRATION; NEOPLASMS; PACLITAXEL; RECEPTOR, EPIDERMAL GROWTH FACTOR; SPORES, BACTERIAL; STREPTAVIDIN;

EID: 84879776704     PISSN: 1061186X     EISSN: 10292330     Source Type: Journal    
DOI: 10.3109/1061186X.2013.778262     Document Type: Article

References (39)

1. Ghosh P, Han G, De M, et al. Gold nanoparticles in delivery applications. Adv Drug Deliv Rev 2008;60:1307-15.
2. Sun C, Lee JSH, Zhang M. Magnetic nanoparticles in MR imaging and drug delivery. Adv Drug Deliv Rev 2008;60:1252-65.
3. Patel T, Zhou J, Piepmeier J, Saltzman W. Polymeric nanoparticles for drug delivery to the central nervous system. Adv Drug Deliv Rev 2012;64:701-5.
4. Jong WHD, Borm PJA. Drug delivery and nanoparticles: applications and hazards. Int J Nanomed 2008;3:133-49.
5. Maletzki C, Gock M, Klier U, et al. Bacteriolytic therapy of experimental pancreatic carcinoma. World J Gastroenterol 2010;16: 3546-52.
6. Theys J, Pennington O, Dubois L, et al. Repeated cycles of clostridium-directed enzyme prodrug therapy result in sustained antitumour effects in vivo. Br J Cancer 2006;95:1212-19.
7. Liu SC, Ahn GO, Kioi M, et al. Optimized clostridium-directed enzyme prodrug therapy improves the antitumor activity of the novel DNA cross-linking agent PR-104. Cancer Res 2008;68: 7995-8003.
8. Hong HA, Le HD, Cutting SM. The use of bacterial spore formers as probiotics. FEMS Microbiol Rev 2005;29:813-35.
9. Huang JM, Huynh HA, Hoang TV, et al. Mucosal delivery of antigens using adsorption to bacterial spores. Vaccine 2010;28: 1021-30.
10. Henriques AO, Moran Jr CP. Structure, assembly, and function of the spore surface layers. Annu Rev Microbiol 2007;61:555-88.
11. Song M, Hong HA, Huang JM, et al. Killed Bacillus subtilis spores as a mucosal adjuvant for an H5N1. Vaccine 2012;22:3266-77.
12. Ricca E, Cutting SM. Emerging applications of bacterial spores in nanobiotechnology. J Nanobiotechnol 2003;1:6-16.
13. Le DH, Huynh HA, Fairweather N, et al. Bacterial spores as vaccine vehicles. Infect Immun 2003;71:2810-18.
14. Le DH, Huynh HA, Atkins HS, et al. Immunization against anthrax using Bacillus subtilis spores expressing the anthrax protective antigen. Vaccine 2006;25:346-55.
15. Cutting SM. Spores as oral vaccines. In: Ricca E, Henriques AO, Cutting SM, eds. Bacterial spore formers: probiotics and emerging applications. Norfolk: Horizon Bioscience Press; 2004: 201-6.
16. Mauriello EMF. Display of heterologous antigens on the Bacillus subtilis spore coat using CotC as a fusion partner. Vaccine 2004;22: 1177-87.
17. Kim LH, Lee CS, Kim BG. Spore-displayed streptavidin: a live diagnostic tool in biotechnology. Biochem Biophys Res Commun 2005;331:210-14.
18. Green NM. Avidin and streptavidin. Methods Enzymol 1990;84: 51-67.
19. Qureshi, MH, Wong SL. Design, production, and characterization of a monomeric streptavidin and its application for affinity purification of biotinylated proteins. Protein Express Purification 2002;25:409-15.
20. Wilchek M, Bayer EA, Livnah O. Essentials of biorecognition: the streptavidin-biotin system as a model for protein-protein and protein-ligand interaction. Immunol Lett 2006;103:27-32.
21. Mendelsohn J, Baselga J. The EGF receptor family as targets for cancer therapy. Oncogene 2000;19:6550-65.
22. Sanford D, Markowitz SD, Bertagnolli M. Molecular basis of colorectal cancer. New Engl J Med 2009;361:2449-60.
23. Jhawer M. PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab. Cancer Res 2008;68:1953-61.
24. Mckay JA, Murray LJ, Curran S. Evaluation of the epidermal growth factor receptor (EGFR) in colorectal tumours and lymph node metastases. Eur J Cancer 2002;38:2258-64.
25. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. New Eng J Med 2008;351:337-45.
26. Horwitz SB. Mechanism of action of taxol. Trends Pharmacol Sci 1992;13:134-6.
27. Sambrook J, Fritsch EF, Maniatis T. Molecular cloning: a laboratory manual. 2nd ed. Cold Spring Harbor (NY): Cold Spring Harbor Laboratory; 1989.
28. Cutting SM, Vander Horn PB. Genetic analysis. In: Harwood CR, Cutting SM, eds. Molecular biological methods for Bacillus. Chichester, UK: Wiley; 1990:27-74.
29. Isticato R, Cangiano G, Tran HT, et al. Surface display of recombinant proteins on Bacillus subtilis spores. J Bacteriol 2001; 183:6294-301.
30. Nicholson WL, Setlow P. Sporulation, germination, and outgrowth. In: Harwood CR, Cutting SM, eds. Molecular biological methods for Bacillus. Sussex, UK: Wiley;1990; 391-450.
31. Nguyen TVA, Kamio Y, Higuchi H. Single-molecule imaging of cooperative assembly of g-hemolysin on erythrocyte membranes. EMBO J 2003;22:4968-79.
32. Nguyen HA, Nguyen TVA, Kamio Y, Higuchi H. Singlemolecule environment-sensitive fluorophores inserted into cell membranes by staphylococcal g-hemolysin. Biochemistry 2006;45: 2570-6.
33. Mariadason JM, Arango D, Qiuhu S, et al. Gene expression profiling-based prediction of response of colon carcinoma cells to 5-fluorouracil and camptothecin. Cancer Res 2003;63:8791-812.
34. Kurebayashi J, Otsuki T, Tang CK, et al. Isolation and characterization of a new human breast cancer cell line, KPL-4, expressing the Erb B family receptors and interleukin-6. Br J Cancer 1999;79: 707-17.
35. Fujimoto-Ouchi K, Sekiguchi F, Tanaka Y. Antitumor activity of combinations of anti-HER-2 antibody trastuzumab and oral fluoropyrimidines capecitabine/50-dFUrd in human breast cancer models. Cancer Chemother Pharmacol 2002;49:211-16.
36. Tada H, Higuchi H, Watanabe TM, Ohuchi N. In vivo real-time tracking of single quantum dots conjugated with monoclonal anti-HER2 antibody in tumors of mice. Cancer Res 2007;67:1138-44.
37. Xu H, Yu Y, Marciniak D, et al. Epidermal growth factor receptor (EGFR)-related protein inhibits multiple members of the EGFR family in colon and breast cancer cells. Mol Cancer Ther 1989;4: 435-42.
38. Huynh H, To E, Fakhry S, et al. Defining the natural habitat of Bacillus spore-formers. Res Microbiol 2009;160:134-43.
39. Li Y, Edsall Jr R, Jagtap PG, et al. Equilibrium studies of a fluorescent paclitaxel derivative binding to microtubules. Biochemistry 2000;39:616-23.